Related Experiment Video

Updated: Jun 23, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

The calcium channel antagonist debate: recent developments

J Lubsen1

  • 1SOCAR Research SA, Nyon, Switzerland.

European Heart Journal
|September 22, 1998
PubMed

Insights

Calcium channel antagonists (CCAs) show benefits in older adults with systolic hypertension but may increase heart attack risk in diabetics. Current guidelines recommend diuretics and beta-blockers first for hypertension management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure has influenced hypertension treatment guidelines.
  • Recent studies have introduced new evidence regarding the efficacy and safety of calcium channel antagonists (CCAs).
  • The ongoing debate questions the evidence-based medicine supporting current CCA recommendations.

Purpose of the Study:

  • To evaluate the cardiovascular outcomes associated with CCA use in specific hypertensive populations.
  • To assess the comparative risks and benefits of CCAs against other antihypertensive agents.
  • To review the latest evidence concerning CCA use in hypertension management.

Main Methods:

  • A placebo-controlled trial involving 4695 patients to assess nitrendipine's effect on cardiovascular complications.
  • A 470-patient trial comparing nisoldipine (CCA) with enalapril (ACE inhibitor) in diabetic hypertensive patients.
  • Analysis of non-experimental data (84,093 person-years) on antihypertensive agents in women.
  • A case-control study (9513 cases, 6492 controls) investigating CCA and cancer risk.

Main Results:

  • Nitrendipine significantly reduced cardiovascular complications in older adults with systolic hypertension.
  • Nisoldipine was associated with a higher rate of myocardial infarction in diabetic patients compared to enalapril.
  • Non-experimental data showed mostly non-significant mortality differences, complicated by potential confounding.
  • A suggested link between CCAs and suicide requires further investigation; however, CCAs are unlikely to cause cancer.

Conclusions:

  • While diuretics and beta-blockers remain first-line treatments for hypertension, sustained-release CCAs may be considered for patients uncontrolled on other agents.
  • CCA use requires careful consideration of patient-specific factors, particularly in diabetic populations.
  • Further research is needed to clarify the association between CCAs and suicide risk.

More Related Videos

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...